false 0001175505 0001175505 2025-11-10 2025-11-10





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2020



Five Prime Therapeutics, Inc.

(Exact name of registrant as specified in its charter)




Delaware   001-36070   26-0038620

(state or other jurisdiction

of incorporation)



File Number)


(I.R.S. Employer

Identification No.)


111 Oyster Point Boulevard

South San Francisco, California

(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (415) 365-5600


(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class





Name of Each Exchange

on Which Registered

Common Stock, par value $0.001 per share   FPRX   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




Item 8.01

Other Events.

On November 10, 2020, Five Prime Therapeutics, Inc. (“FivePrime”) issued a press release announcing that all three efficacy endpoints in the global, randomized, double-blind placebo-controlled Phase 2 FIGHT clinical trial evaluating bemarituzumab in combination with mFOLFOX6 in patients with previously untreated advanced FGFR2b+, non-HER2+ gastric or gastroesophageal junction cancer (the “FIGHT Trial”) met pre-specified statistical significance for the combination of bemarituzumab with mFOLFOX6 as compared to the combination of placebo with mFOLFOX6. The primary endpoint in the FIGHT Trial was progression-free survival, and the secondary efficacy endpoints were overall survival and objective response rate.

FivePrime also posted a slide presentation to its website that includes information regarding the FIGHT Trial results.

A copy of the press release and slide presentation are filed herewith as Exhibits 99.1 and Exhibit 99.2, respectively, and the information contained in each of the press release and the slide presentation is incorporated by reference into this Current Report on Form 8-K.


Item 9.01.

Financial Statements and Exhibits.








99.1    Press release issued by FivePrime on November 10, 2020
99.2    Slide presentation
104    Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Five Prime Therapeutics, Inc.

/s/ Francis Sarena

  Francis Sarena
  Chief Strategy Officer and Secretary

Dated: November 10, 2020